Ho-ho-ho! Gather around, my dear friends, for I have a tale as intriguing as the mystery of how I manage to deliver all those presents in one night. This story, however, doesn’t involve reindeer or sleighs but something equally magical in its own realm – the world of medicine. It’s about the wondrous effects of Direct-acting Antiviral Agents (DAAs) on those naughty or nice lipid levels in patients with Hepatitis C virus (HCV).

In the bustling workshop of science, researchers, much like my elves, have been diligently searching through the grand libraries of PubMed, Web of Science, Embase, and Central databases, with their quest coming to a climax in September 2023. Their mission? To unwrap the mysteries of how DAAs, when used to treat hepatitis C, affect lipid parameters post-treatment, aiming for what they call a sustained viral response (SVR) – a bit like making sure the toys last well past Christmas morning.

From their sack of 32 studies, they found that, much like the joy of Christmas morning, total cholesterol (TC) levels and low-density lipoprotein (LDL) levels saw a rise from the end of treatment to one year after, bringing good tidings of great joy (or at least better lipid profiles). High-density lipoprotein (HDL) levels, those helpers of the heart, also got a boost, starting from 4 weeks after treatment and lasting up to 24 weeks. However, triglyceride (TG) levels, those tricky little elves, showed no significant change, staying on their best behavior.

So, my dear friends, as we sip our hot cocoa and enjoy the warmth of the fireplace, let’s marvel at how Hepatitis C patients who achieved SVR with DAAs not only saw their lipid levels rise but also witnessed the improvement of hepatic inflammation indicators AST and ALT. This tale, registered under the magical number PROSPERO CRD42020180793, provides the evidence-based medical evidence needed for the follow-up and monitoring of blood lipids and the treatment of hyperlipidemia, ensuring a healthier future for all, and to all a good night!